Literature DB >> 10064262

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy.

G J Moyle1, M Sadler, N Buss.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064262     DOI: 10.1086/517200

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 2.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

3.  Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Authors:  Caroline Solas; Alain Lafeuillade; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 4.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

Review 5.  Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.

Authors:  Andrea Calcagno; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

Review 6.  Clinical implications of CNS penetration of antiretroviral drugs.

Authors:  Heather E Wynn; Richard C Brundage; Courtney V Fletcher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

Authors:  Aylin Yilmaz; Dietmar Fuchs; Lars Hagberg; Ulrika Nillroth; Lars Ståhle; Jan-Olof Svensson; Magnus Gisslén
Journal:  BMC Infect Dis       Date:  2006-03-27       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.